Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497245 | 0.87 | SMPD3 (0.40) | RXFP1KDM4ESMPD3ALDH1A1HPGD | |
| SCHEMBL31082622 | 0.85 | LMNA (0.41) | RXFP1KDM4ESMPD3ALDH1A1HPGD | |
| SCHEMBL31600992 | 0.83 | KMT2A (0.41) | KDM4ESMPD3ALDH1A1HPGDHSD17B10 | |
| SCHEMBL26664189 | 0.81 | RXFP1 (0.35) | RXFP1KDM4ESMPD3ALDH1A1HPGD | |
| SCHEMBL26978235 | 0.80 | ASPH (0.41) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3755198 | 0.77 | APOBEC3A (0.49) | RXFP1APOBEC3AAPOBEC3GKDM4EALDH1A1 | |
| SCHEMBL22445908 | 0.77 | APOBEC3A (0.41) | RXFP1APOBEC3AAPOBEC3GKDM4EALDH1A1 | |
| SCHEMBL3970342 | 0.76 | KDM4E (0.52) | KDM4ESMPD3ALDH1A1HPGDHSD17B10 | |
| SCHEMBL28524393 | 0.75 | APOBEC3A (0.41) | RXFP1APOBEC3AAPOBEC3GKDM4EALDH1A1 | |
| SCHEMBL25151525 | 0.75 | KDM4E (0.45) | KDM4ESMPD3ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025111409-A1 | HETEROCYCLIC COMPOUNDS OF FORMULA (I) FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY VIA MODULATION OF SMN2 SPLICING | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4308572-B1 | NEW THIENOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | disclosed |
| CN-119866329-A | Heterocyclic compounds for the treatment of huntington's disease | 渤健马萨诸塞州股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-4526292-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024182788-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240182493-A1 | PROCESS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4308572-A1 | NEW THIENOPYRIMIDINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308578-A2 | PROCESS FOR PREPARING RISDIPLAM | F. Hoffmann-La Roche AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002407-A1 | THIENOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-117050096-A | Preparation method of risperidone | 杭州诺澳生物医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117015546-A | Process for preparing Li Sipu blue | 豪夫迈·罗氏有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116997555-A | Novel thienopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2022194800-A1 | NEW THIENOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | RXFP1 4463/4885APOBEC3A 4200/4885APOBEC3G 4446/4885 |
| US-20240002407-A1 | THIENOPYRIMIDINONE DERIVATIVES | XDH, P2RX4, TBXA2R | RXFP1 309/4885APOBEC3A 4369/4885APOBEC3G 4363/4885 |
| US-20240182493-A1 | PROCESS | CYP3A7, UGT2B7, UGT1A7 | RXFP1 3836/4885APOBEC3A 1011/4885APOBEC3G 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.